Characterization of a SHIV162P3 variant evolved in an infected rhesus macaque with persistent plasma viremia

Virus Research

Volumn 151, Issue 2, 2010, Pages 229-234

  Chung, Hye Kyung ^a   Suschak, John ^a   Galmin, Lindsey ^a   Rose, Nicholas ^a   Pal, Ranajit ^a  

^a ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

Author keywords

HIV; Neutralizing antibody; Plasma viremia; Rhesus macaque; SHIV

Indexed keywords

GLYCOPROTEIN GP 120; MARAVIROC; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY B12; SOLUBLE CD4 ANTIGEN; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYCLOHEXANE DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY; TRIAZOLE DERIVATIVE; VIRUS ENVELOPE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SEQUENCE; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; ENVELOPE GENE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MACACA; NONHUMAN; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIMIAN HUMAN IMMUNODEFICIENCY VIRUS; VIREMIA; VIRUS GENE; VIRUS RECOMBINANT; AMINO ACID SUBSTITUTION; ANIMAL; CD4 LYMPHOCYTE COUNT; DNA SEQUENCE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; MISSENSE MUTATION; PLASMA; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIROLOGY;

AMINO ACID SUBSTITUTION; ANIMALS; ANTI-HIV AGENTS; ANTIBODIES, NEUTRALIZING; CD4 LYMPHOCYTE COUNT; CYCLOHEXANES; GENE PRODUCTS, ENV; HIV ANTIBODIES; MACACA MULATTA; MALE; MUTATION, MISSENSE; PLASMA; SEQUENCE ANALYSIS, DNA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TRIAZOLES; VIREMIA;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA MULATTA; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77954213065     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2010.04.006     Document Type: Article

References (44)

1. Baba T.W., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehunie S., Cavacini L.A., Posner M.R., Katinger H., Stiegler G., Bernacky B.J., Rizvi T.A., Schmidt R., Hill L.R., Keeling M.E., Lu Y., Wright J.E., Chou T.C., Ruprecht R.M. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 2000, 6(2):200-206.
2. Binley J.M., Lybarger E.A., Crooks E.T., Seaman M.S., Gray E., Davis K.L., Decker J.M., Wycuff D., Harris L., Hawkins N., Wood B., Nathe C., Richman D., Tomaras G.D., Bibollet-Ruche F., Robinson J.E., Morris L., Shaw G.M., Montefiori D.C., Mascola J.R. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 2008, 82(23):11651-11668.
3. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 2004, 78(23):13232-13252.
4. Boom R., Sol C.J., Salimans M.M., Jansen C.L., Wertheim-van Dillen P.M., van der Noordaa J. Rapid and simple method for purification of nucleic acids. J. Clin. Microbiol. 1990, 28(3):495-503.
5. Bunnik E.M., van Gils M.J., Lobbrecht M.S., Pisas L., van Nuenen A.C., Schuitemaker H. Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection. Virology 2009, 390(2):348-355.
6. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., Sawyer L.S., Hendry R.M., Dunlop N., Nara P.L., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266(5187):1024-1027.
7. Cayabyab M., Karlsson G.B., Etemad-Moghadam B.A., Hofmann W., Steenbeke T., Halloran M., Fanton J.W., Axthelm M.K., Letvin N.L., Sodroski J.G. Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2). J. Virol. 1999, 73(2):976-984.
8. Cayabyab M., Rohne D., Pollakis G., Mische C., Messele T., Abebe A., Etemad-Moghadam B., Yang P., Henson S., Axthelm M., Goudsmit J., Letvin N.L., Sodroski J. Rapid CD4+ T-lymphocyte depletion in rhesus monkeys infected with a simian-human immunodeficiency virus expressing the envelope glycoproteins of a primary dual-tropic Ethiopian Clade C HIV type 1 isolate. AIDS Res. Hum. Retroviruses 2004, 20(1):27-40.
9. Chung H.K., Pise-Masison C.A., Radonovich M.F., Brady J., Lee J.K., Cheon S.Y., Markham P., Cristillo A., Pal R. Cellular gene expression profiles in rhesus macaques challenged mucosally with a pathogenic R5 tropic simian-human immunodeficiency virus isolate. Viral Immunol. 2008, 21(4):411-423.
10. Cristillo A.D., Lisziewicz J., He L., Lori F., Galmin L., Trocio J.N., Unangst T., Whitman L., Hudacik L., Bakare N., Whitney S., Restrepo S., Suschak J., Ferrari M.G., Chung H.K., Kalyanaraman V.S., Markham P., Pal R. HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. Virology 2007, 366(1):197-211.
11. Doria-Rose N.A., Klein R.M., Manion M.M., O'Dell S., Phogat A., Chakrabarti B., Hallahan C.W., Migueles S.A., Wrammert J., Ahmed R., Nason M., Wyatt R.T., Mascola J.R., Connors M. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J. Virol. 2009, 83(1):188-199.
12. Duenas-Decamp M.J., Peters P., Burton D., Clapham P.R. Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop. J. Virol. 2008, 82(12):5807-5814.
13. Easterbrook P.J. Long-term non-progression in HIV infection: definitions and epidemiological issues. J. Infect. 1999, 38(2):71-73.
14. Grabar S., Selinger-Leneman H., Abgrall S., Pialoux G., Weiss L., Costagliola D. Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS 2009, 23(9):1163-1169.
15. Harouse J.M., Gettie A., Eshetu T., Tan R.C., Bohm R., Blanchard J., Baskin G., Cheng-Mayer C. Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J. Virol. 2001, 75(4):1990-1995.
16. Harouse J.M., Gettie A., Tan R.C., Blanchard J., Cheng-Mayer C. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 1999, 284(5415):816-819.
17. Hessell A.J., Poignard P., Hunter M., Hangartner L., Tehrani D.M., Bleeker W.K., Parren P.W., Marx P.A., Burton D.R. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 2009, 15(8):951-954.
18. Hessell A.J., Rakasz E.G., Poignard P., Hangartner L., Landucci G., Forthal D.N., Koff W.C., Watkins D.I., Burton D.R. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009, 5(5):e1000433.
19. Igarashi T., Donau O.K., Imamichi H., Dumaurier M.J., Sadjadpour R., Plishka R.J., Buckler-White A., Buckler C., Suffredini A.F., Lane H.C., Moore J.P., Martin M.A. Macrophage-tropic simian/human immunodeficiency virus chimeras use CXCR4, not CCR5, for infections of rhesus macaque peripheral blood mononuclear cells and alveolar macrophages. J. Virol. 2003, 77(24):13042-13052.
20. Keele B.F., Giorgi E.E., Salazar-Gonzalez J.F., Decker J.M., Pham K.T., Salazar M.G., Sun C., Grayson T., Wang S., Li H., Wei X., Jiang C., Kirchherr J.L., Gao F., Anderson J.A., Ping L.H., Swanstrom R., Tomaras G.D., Blattner W.A., Goepfert P.A., Kilby J.M., Saag M.S., Delwart E.L., Busch M.P., Cohen M.S., Montefiori D.C., Haynes B.F., Gaschen B., Athreya G.S., Lee H.Y., Wood N., Seoighe C., Perelson A.S., Bhattacharya T., Korber B.T., Hahn B.H., Shaw G.M. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U.S.A. 2008, 105(21):7552-7557.
21. Kraft Z., Derby N.R., McCaffrey R.A., Niec R., Blay W.M., Haigwood N.L., Moysi E., Saunders C.J., Wrin T., Petropoulos C.J., McElrath M.J., Stamatatos L. Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies. J. Virol. 2007, 81(12):6402-6411.
22. Lee E.M., Chung H.K., Livesay J., Suschak J., Finke L., Hudacik L., Galmin L., Bowen B., Markham P., Cristillo A., Pal R. Molecular methods for evaluation of virological status of nonhuman primates challenged with simian immunodeficiency or simian-human immunodeficiency viruses. J. Virol. Methods. 2010, 163(2):287-294.
23. Li Y., Svehla K., Louder M.K., Wycuff D., Phogat S., Tang M., Migueles S.A., Wu X., Phogat A., Shaw G.M., Connors M., Hoxie J., Mascola J.R., Wyatt R. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J. Virol. 2009, 83(2):1045-1059.
24. Liu Z.Q., Muhkerjee S., Sahni M., McCormick-Davis C., Leung K., Li Z., Gattone V.H., Tian C., Doms R.W., Hoffman T.L., Raghavan R., Narayan O., Stephens E.B. Derivation and biological characterization of a molecular clone of SHIV(KU-2) that causes AIDS, neurological disease, and renal disease in rhesus macaques. Virology 1999, 260(2):295-307.
25. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 2000, 6(2):207-210.
26. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Ruker F., Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 1993, 67(11):6642-6647.
27. Pal R., Taylor B., Foulke J.S., Woodward R., Merges M., Praschunus R., Gibson A., Reitz M. Characterization of a simian-human immunodeficiency virus encoding the envelope gene from the CCR5-tropic HIV-1 Ba-L. J. Acquir. Immune Defic. Syndr. 2003, 33(3):300-307.
28. Pantophlet R., Ollmann Saphire E., Poignard P., Parren P.W., Wilson I.A., Burton D.R. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J. Virol. 2003, 77(1):642-658.
29. Parren P.W., Marx P.A., Hessell A.J., Luckay A., Harouse J., Cheng-Mayer C., Moore J.P., Burton D.R. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 2001, 75(17):8340-8347.
30. Reimann K.A., Li J.T., Veazey R., Halloran M., Park I.W., Karlsson G.B., Sodroski J., Letvin N.L. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 1996, 70(10):6922-6928.
31. Romano J.W., Shurtliff R.N., Dobratz E., Gibson A., Hickman K., Markham P.D., Pal R. Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology. J. Virol. Methods 2000, 86(1):61-70.
32. Romano J.W., Shurtliff R.N., Sarngadharan M.G., Pal R. Detection of HIV-1 infection in vitro using NASBA: an isothermal RNA amplification technique. J. Virol. Methods 1995, 54(2-3):109-119.
33. Ruprecht R.M. Passive immunization with human neutralizing monoclonal antibodies against HIV-1 in macaque models: experimental approaches. Methods Mol. Biol. 2009, 525:559-566. xiv.
34. Rusert P., Kuster H., Joos B., Misselwitz B., Gujer C., Leemann C., Fischer M., Stiegler G., Katinger H., Olson W.C., Weber R., Aceto L., Gunthard H.F., Trkola A. Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J. Virol. 2005, 79(13):8454-8469.
35. Saksena N.K., Rodes B., Wang B., Soriano V. Elite HIV controllers: myth or reality?. AIDS Rev. 2007, 9(4):195-207.
36. Sather D.N., Armann J., Ching L.K., Mavrantoni A., Sellhorn G., Caldwell Z., Yu X., Wood B., Self S., Kalams S., Stamatatos L. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 2009, 83(2):757-769.
37. Shibata R., Igarashi T., Haigwood N., Buckler-White A., Ogert R., Ross W., Willey R., Cho M.W., Martin M.A. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 1999, 5(2):204-210.
38. Siddappa N.B., Song R., Kramer V.G., Chenine A.L., Velu V., Ong H., Rasmussen R.A., Grisson R.D., Wood C., Zhang H., Kankasa C., Amara R.R., Else J.G., Novembre F.J., Montefiori D.C., Ruprecht R.M. Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection. J. Virol. 2009, 83(3):1422-1432.
39. Song R.J., Chenine A.L., Rasmussen R.A., Ruprecht C.R., Mirshahidi S., Grisson R.D., Xu W., Whitney J.B., Goins L.M., Ong H., Li P.L., Shai-Kobiler E., Wang T., McCann C.M., Zhang H., Wood C., Kankasa C., Secor W.E., McClure H.M., Strobert E., Else J.G., Ruprecht R.M. Molecularly cloned SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env. J. Virol. 2006, 80(17):8729-8738.
40. Stamatatos L., Morris L., Burton D.R., Mascola J.R. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nat. Med. 2009, 15(8):866-870.
41. Stiegler G., Kunert R., Purtscher M., Wolbank S., Voglauer R., Steindl F., Katinger H. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 2001, 17(18):1757-1765.
42. Trkola A., Kuster H., Rusert P., Joos B., Fischer M., Leemann C., Manrique A., Huber M., Rehr M., Oxenius A., Weber R., Stiegler G., Vcelar B., Katinger H., Aceto L., Gunthard H.F. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 2005, 11(6):615-622.
43. Trkola A., Pomales A.B., Yuan H., Korber B., Maddon P.J., Allaway G.P., Katinger H., Barbas C.F., Burton D.R., Ho D.D., et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 1995, 69(11):6609-6617.
44. Valdez H., Carlson N.L., Post A.B., Asaad R., Heeger P.S., Lederman M.M., Lehmann P.V., Anthony D.D. HIV long-term non-progressors maintain brisk CD8 T cell responses to other viral antigens. AIDS 2002, 16(8):1113-1118.